

*Disclaimer :*

*The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.*

## **M. 9044 - CVC / RECORDATI**

### **SECTION 1.2**

#### **Description of the concentration**

On 26 October 2018, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) 139/2004 involving the acquisition of the sole control of Recordati S.p.A., together with its direct and indirect subsidiaries (the "**Target**") by CVC Capital Partners SICAV-FIS S.A. ("**CVC**") within the meaning of Article 3(1)(b) of Council Regulation No 139/2004.

The primary business activities of the undertakings are:

- a) For CVC, CVC and/or its subsidiaries manage investment funds and platforms. CVC Funds Portfolio Companies in the pharmaceutical sector include:
  - 1) **Alvogen** – a global producer of generic, branded and biosimilar products for use in oncology, cardiology, respiratory, neurology and gastroenterology treatments;
  - 2) **DOC Generici** – a generic pharmaceutical company in Italy selling products across a range of therapeutic areas including cardiovascular, gastroenterology and neurology; and
  - 3) **Theramex** – a global specialty pharmaceutical company dedicated to women's health products
- b) The Target's product portfolio comprises pharmaceuticals both generic and under licence, including a number of drugs for the treatment of rare diseases. It includes drugs for the treatment of hypertension and other cardiovascular disorders, disorders of the lower urinary tract as well as drugs for treatment of rare diseases such as metabolic deficiencies of a genetic nature.